Areteia Therapeutics Posts Phase 3 Win for Oral Asthma Drug Dexpramipexole
Areteia Therapeutics reported positive topline results from its pivotal Phase 3 EXHALE-4 trial evaluating dexpramipexole, an oral therapy for eosinophilic asthma51.
Dexpramipexole is a first-in-class small molecule designed to block maturation and release of eosinophils, targeting the underlying mechanism of eosinophilic asthma24.
Phase 3 data shows that oral dexpramipexole as an add-on treatment resulted in statistically significant improvements in lung function compared to placebo in patients with eosinophilic asthma15.
This drug could potentially challenge current biologic blockbusters dominating severe asthma treatment, as dexpramipexole is administered orally and may improve patient access4.
Areteia's EXHALE-4 trial is one of several global Phase 3 studies (EXHALE-2,3,4), with topline results from EXHALE-4 announced in 2025345.
Areteia highlighted its progress and milestones at the 43rd J.P. Morgan Annual Healthcare Conference, emphasizing dexpramipexole's transformative potential in respiratory health47.
Sources:
1. https://www.hcplive.com/view/dexpramipexole-oral-add-on-asthma-significantly-improves-lung-function-placebo
2. https://medcitynews.com/2022/07/areteia-gets-350m-to-turn-failed-als-drug-into-a-therapy-for-severe-asthma/
4. https://www.pharmaceutical-technology.com/analyst-comment/driving-innovation-respiratory-health-areteias-2025-milestones-future-goals/